Triall Insights 🔍
57% of clinical trials initiated in 2022 were conducted by non-industry sponsors such as academic hospitals and institutions.
These studies are predominantly single-country trials based in the US or China.
Source: globaldata.com/store/report/clinical-trial-investigations-ranking-analysis/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1688506256800034816?s=20
#blockchainforhealth #TRL
57% of clinical trials initiated in 2022 were conducted by non-industry sponsors such as academic hospitals and institutions.
These studies are predominantly single-country trials based in the US or China.
Source: globaldata.com/store/report/clinical-trial-investigations-ranking-analysis/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1688506256800034816?s=20
#blockchainforhealth #TRL
Staking pool closing soon 💎
Our $TRL staking pool is closing in 2 days!
The BSC Holder 8 (8% APR) pool is available on BSC and runs for 100 days.
👉 Start staking today at triall.io/staking
New to $TRL staking?
✅ Whitelist yourself: bit.ly/TRLwhitelist
📋 Read the guide: bit.ly/stakingTRL
Staking tech is powered by Ferrum Network.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1689247194774216705?s=20
#blockchainforhealth #TRL
Our $TRL staking pool is closing in 2 days!
The BSC Holder 8 (8% APR) pool is available on BSC and runs for 100 days.
👉 Start staking today at triall.io/staking
New to $TRL staking?
✅ Whitelist yourself: bit.ly/TRLwhitelist
📋 Read the guide: bit.ly/stakingTRL
Staking tech is powered by Ferrum Network.
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1689247194774216705?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
42% of clinical trial terminations across 2022 occurred in phase 2 studies.
The most prominent reasons for termination were business/strategic decisions and low accrual rates.
Source: globaldata.com/store/report/clinical-trial-investigations-ranking-analysis/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1691042341010690049?s=20
#blockchainforhealth #TRL
42% of clinical trial terminations across 2022 occurred in phase 2 studies.
The most prominent reasons for termination were business/strategic decisions and low accrual rates.
Source: globaldata.com/store/report/clinical-trial-investigations-ranking-analysis/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1691042341010690049?s=20
#blockchainforhealth #TRL
Meet us at Digital Demo Day 🇩🇪
Tomorrow, Triall co-founder Ray will join the startup pitch competition of #DDD23 in Germany.
Next to pitching, we’ll be hosting a booth to demo the prototype of our Clinical Insights Exchange.
DDD23 is the seventh edition of Germany’s largest B2B startup expo & conference.
The event brings together over 4,500 visitors from corporations, SMEs, investors, and startups to discuss HealthTech, GreenTech, and DeepTech.
Also present? Visit our booth (A9a) for a live demo!
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1691766989881020767?s=20
#blockchainforhealth #TRL
Tomorrow, Triall co-founder Ray will join the startup pitch competition of #DDD23 in Germany.
Next to pitching, we’ll be hosting a booth to demo the prototype of our Clinical Insights Exchange.
DDD23 is the seventh edition of Germany’s largest B2B startup expo & conference.
The event brings together over 4,500 visitors from corporations, SMEs, investors, and startups to discuss HealthTech, GreenTech, and DeepTech.
Also present? Visit our booth (A9a) for a live demo!
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1691766989881020767?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
94% of technology vendors list risk aversion as a top implementation barrier for patient-facing digital technologies in clinical trials.
Early partnerships, decision-maker engagement, and rapid experimentation were mentioned as key ways to overcome implementation barriers.
Source: transceleratebiopharmainc.com/assets/patient-technology-implementation-framework/patient-technology-assets/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1693591725560729980?s=20
#blockchainforhealth #TRL
94% of technology vendors list risk aversion as a top implementation barrier for patient-facing digital technologies in clinical trials.
Early partnerships, decision-maker engagement, and rapid experimentation were mentioned as key ways to overcome implementation barriers.
Source: transceleratebiopharmainc.com/assets/patient-technology-implementation-framework/patient-technology-assets/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1693591725560729980?s=20
#blockchainforhealth #TRL
Triall at Digital Demo Day 2023 🇩🇪
And that’s a wrap! Last week we took the stage at Digital Demo Day (#DDD23) in Düsseldorf, Germany.
Triall co-founder Ray presented in the event’s startup pitch competition, showcasing our product & vision for clinical research.
As the name suggests DDD23 was all about showcasing new technology and we were proud to present a prototype of our Clinical Insights Exchange at a dedicated demo booth throughout the event.
A special shoutout to Digital Innovation Hub Düsseldorf/Rheinland for organising this event!
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1693959718446727659?s=20
#blockchainforhealth #TRL
And that’s a wrap! Last week we took the stage at Digital Demo Day (#DDD23) in Düsseldorf, Germany.
Triall co-founder Ray presented in the event’s startup pitch competition, showcasing our product & vision for clinical research.
As the name suggests DDD23 was all about showcasing new technology and we were proud to present a prototype of our Clinical Insights Exchange at a dedicated demo booth throughout the event.
A special shoutout to Digital Innovation Hub Düsseldorf/Rheinland for organising this event!
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1693959718446727659?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
78% of clinical research professionals trust that Risk-Based Quality Management (RBQM) will improve clinical trial quality.
A majority of respondents say a lack of cross-functional awareness is the top adoption barrier for RBQM.
Source: csdd.tufts.edu/impact-reports
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1696114460111315322?s=20
#blockchainforhealth #TRL
78% of clinical research professionals trust that Risk-Based Quality Management (RBQM) will improve clinical trial quality.
A majority of respondents say a lack of cross-functional awareness is the top adoption barrier for RBQM.
Source: csdd.tufts.edu/impact-reports
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1696114460111315322?s=20
#blockchainforhealth #TRL
Triall at Nordic Blockchain Conference 🇩🇰
Triall co-founder Ray will be speaking at a panel discussion during Nordic Blockchain Conference 2023 in Copenhagen, Denmark.
The Nordic Blockchain Conference provides a meeting ground for the largest #Web3 community in the Nordics.
The panel will dive into practical applications of blockchain in healthcare and clinical research. Moreover, each panelist will cover key challenges, lessons learned, and future outlooks for this emerging field.
🎙️ Panelists:
- Anca Petre (Moderator) - CEO, 23 Consulting
- Eberhard Scheuer - Foundation President, DHealth Foundation
- Jim Nasr - CEO, Acoer
- Lars Øster Hyltoft - Digital Quality Director, Novo Nordisk
- Raymond van der Waal - Co-founder, Triall
🗣 Help spread the news on Twitter:
https://twitter.com/triallofficial/status/1696847411174404397?s=20
#blockchainforhealth #TRL
Triall co-founder Ray will be speaking at a panel discussion during Nordic Blockchain Conference 2023 in Copenhagen, Denmark.
The Nordic Blockchain Conference provides a meeting ground for the largest #Web3 community in the Nordics.
The panel will dive into practical applications of blockchain in healthcare and clinical research. Moreover, each panelist will cover key challenges, lessons learned, and future outlooks for this emerging field.
🎙️ Panelists:
- Anca Petre (Moderator) - CEO, 23 Consulting
- Eberhard Scheuer - Foundation President, DHealth Foundation
- Jim Nasr - CEO, Acoer
- Lars Øster Hyltoft - Digital Quality Director, Novo Nordisk
- Raymond van der Waal - Co-founder, Triall
🗣 Help spread the news on Twitter:
https://twitter.com/triallofficial/status/1696847411174404397?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience & retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Source: bit.ly/44x5hn7
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1698654598448164980?s=20
#blockchainforhealth #TRL
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience & retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Source: bit.ly/44x5hn7
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1698654598448164980?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
95% of sponsors and CROs have initiatives in place to address the operational challenges that originated from the rapid adoption of decentralised clinical trial methods.
Top priorities include reducing site burden and improving data sharing & collaboration.
Source: veeva.com/resources/veeva-digital-clinical-trials-survey-report/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1701197069409497445?s=20
#blockchainforhealth #TRL
95% of sponsors and CROs have initiatives in place to address the operational challenges that originated from the rapid adoption of decentralised clinical trial methods.
Top priorities include reducing site burden and improving data sharing & collaboration.
Source: veeva.com/resources/veeva-digital-clinical-trials-survey-report/
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1701197069409497445?s=20
#blockchainforhealth #TRL
Research update 🗞️
JMIR Publications published the preprint of Triall's research paper with Mayo Clinic physician Dr. Christopher McLeod.
The preprint concerns a research protocol that marks the 1st publication in an article series on blockchain-based dynamic consent in patient-centric health information sharing & research.
The research set out to review current literature to identify implementations of blockchain-based dynamic consent, the impact of this technology within clinical settings, and to establish best practices for future research & implementations.
Through this exercise, both organisations aim to identify optimal approaches to implementing and studying the effectiveness of blockchain-based dynamic consent technologies.
👉 Article link: https://preprints.jmir.org/preprint/50339
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1701574033366479093?s=20
#DynamicConsent #SSI #JMIR
JMIR Publications published the preprint of Triall's research paper with Mayo Clinic physician Dr. Christopher McLeod.
The preprint concerns a research protocol that marks the 1st publication in an article series on blockchain-based dynamic consent in patient-centric health information sharing & research.
The research set out to review current literature to identify implementations of blockchain-based dynamic consent, the impact of this technology within clinical settings, and to establish best practices for future research & implementations.
Through this exercise, both organisations aim to identify optimal approaches to implementing and studying the effectiveness of blockchain-based dynamic consent technologies.
👉 Article link: https://preprints.jmir.org/preprint/50339
🗣️ Help us spread the news:
https://x.com/triallofficial/status/1701574033366479093?s=20
#DynamicConsent #SSI #JMIR
Triall AMA: Announcing community AMA #16 📺💬
Mark your calendars!
On Oct 5 at 12:00 UTC, Triall will host its 16th community AMA on YouTube, answering live and pre-submitted questions from the Triall community.
🎙 AMA Guests
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Head of Operations
- Raymond van der Waal, Head of Strategic Partnerships
📬 AMA Questions
Submit your questions here: bit.ly/TRLvidAMA16
The 5 best questions get $50 in TRL tokens💰
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1702273237067903390?s=20
#blockchainforhealth #TRL
Mark your calendars!
On Oct 5 at 12:00 UTC, Triall will host its 16th community AMA on YouTube, answering live and pre-submitted questions from the Triall community.
🎙 AMA Guests
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Head of Operations
- Raymond van der Waal, Head of Strategic Partnerships
📬 AMA Questions
Submit your questions here: bit.ly/TRLvidAMA16
The 5 best questions get $50 in TRL tokens💰
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1702273237067903390?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
80% of research site staff are somewhat or very optimistic about the future operating environment for clinical trials.
This optimism is significantly related to the degree to which site staff feel sponsors request, value, and apply feedback from the site.
Source: https://csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1703725443520602281?s=20
#blockchainforhealth #TRL
80% of research site staff are somewhat or very optimistic about the future operating environment for clinical trials.
This optimism is significantly related to the degree to which site staff feel sponsors request, value, and apply feedback from the site.
Source: https://csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1703725443520602281?s=20
#blockchainforhealth #TRL
Triall Insights 🔍
According to a study by IQVIA, decentralised clinical trials can realise a 78% reduction in recruiting time, measured by time from first patient in to last patient in.
Source: iqvia.com/library/white-papers/dcts-deliver-big-roi
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1706262724206788856?s=20
#blockchainforhealth #TRL
According to a study by IQVIA, decentralised clinical trials can realise a 78% reduction in recruiting time, measured by time from first patient in to last patient in.
Source: iqvia.com/library/white-papers/dcts-deliver-big-roi
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help spread the news:
https://x.com/triallofficial/status/1706262724206788856?s=20
#blockchainforhealth #TRL
Partner interview: CRO perspective on digital transformation 🤖
Digital transformation has been a hot topic in clinical research for some time now.
However, digitalisation is not just ‘doing things digitally’ and adopting new technology ways heavy on having the right people and processes in place.
In this interview, we sat down with Nick van den Bulk, Head of Clinical Operations at CR2O, to talk about the company’s digital transformation journey.
We cover the company’s main motivations, the most promising eClinical tools, and key implementation challenges related to digital transformation, including key trends such as #DCTs and #patientcentricity.
Full interview: https://www.triall.io/articles/interview-a-cro-perspective-on-digital-transformation
🗣 Help spread the news:
https://x.com/triallofficial/status/1706628098031014377?s=20
#blockchainforhealth #TRL
Digital transformation has been a hot topic in clinical research for some time now.
However, digitalisation is not just ‘doing things digitally’ and adopting new technology ways heavy on having the right people and processes in place.
In this interview, we sat down with Nick van den Bulk, Head of Clinical Operations at CR2O, to talk about the company’s digital transformation journey.
We cover the company’s main motivations, the most promising eClinical tools, and key implementation challenges related to digital transformation, including key trends such as #DCTs and #patientcentricity.
Full interview: https://www.triall.io/articles/interview-a-cro-perspective-on-digital-transformation
🗣 Help spread the news:
https://x.com/triallofficial/status/1706628098031014377?s=20
#blockchainforhealth #TRL
Introducing the Clinical Insights Exchange 📺
We're thrilled to give you a sneak peek into our CIX marketplace for privacy-friendly reuse of clinical trial data.
The CIX aims to redefine the boundaries of data-informed clinical research.
It allows clinical research professionals to tap into historical clinical trial data and unlock unique insights that inform study design, planning, and feasibility.
This video covers the CIX dataset catalogue, our #SSI wallet for self-sovereign data ownership, and our virtual data assistant Triall GPT, a chat agent that runs on the GPT-4 #LLM.
👉 Video link: https://youtu.be/fVJbdkXmcGc?si=9VDUubudF3_ZPVtl
🗣 Help spread the news:
https://x.com/triallofficial/status/1707355481738563989?s=20
#blockchainforhealth #TRL #CIX
We're thrilled to give you a sneak peek into our CIX marketplace for privacy-friendly reuse of clinical trial data.
The CIX aims to redefine the boundaries of data-informed clinical research.
It allows clinical research professionals to tap into historical clinical trial data and unlock unique insights that inform study design, planning, and feasibility.
This video covers the CIX dataset catalogue, our #SSI wallet for self-sovereign data ownership, and our virtual data assistant Triall GPT, a chat agent that runs on the GPT-4 #LLM.
👉 Video link: https://youtu.be/fVJbdkXmcGc?si=9VDUubudF3_ZPVtl
🗣 Help spread the news:
https://x.com/triallofficial/status/1707355481738563989?s=20
#blockchainforhealth #TRL #CIX
Triall Insights 🔍
70% of research site staff believe that conducting clinical trials has become much more difficult over the past 5 years.
The most commonly reported issues include staffing challenges, study budgets, and protocol complexity.
Source: csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1708804862845022296?s=20
#blockchainforhealth #TRL
70% of research site staff believe that conducting clinical trials has become much more difficult over the past 5 years.
The most commonly reported issues include staffing challenges, study budgets, and protocol complexity.
Source: csdd.tufts.edu/impact-reports
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1708804862845022296?s=20
#blockchainforhealth #TRL
Triall AMA: Session #16 📺💬
Are you joining us tomorrow?
On Oct 5 at 12:00 UTC, Triall will host its 16th community AMA session live on YouTube.
Core members of our team will be answering pre-submitted and live questions from the audience with the 5 best questions winning $50 in TRL.
🎙 AMA Guests
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Head of Operations
- Raymond van der Waal, Head of Strategic Partnerships
🗣 Help us spread the news:
https://x.com/triallofficial/status/1709522067626803240?s=20
#blockchainforhealth #TRL
Are you joining us tomorrow?
On Oct 5 at 12:00 UTC, Triall will host its 16th community AMA session live on YouTube.
Core members of our team will be answering pre-submitted and live questions from the audience with the 5 best questions winning $50 in TRL.
🎙 AMA Guests
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Head of Operations
- Raymond van der Waal, Head of Strategic Partnerships
🗣 Help us spread the news:
https://x.com/triallofficial/status/1709522067626803240?s=20
#blockchainforhealth #TRL
And we’re live once again! 🚨📺💬
Tune in to session 16 of the Triall community AMA 👇
https://www.youtube.com/live/aLSPeWAuKdo?si=kdNfc-g4V0GSYGXZ
Tune in to session 16 of the Triall community AMA 👇
https://www.youtube.com/live/aLSPeWAuKdo?si=kdNfc-g4V0GSYGXZ
Youtube
- YouTube
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
Triall Insights 🔍
According to an industry-wide survey, 87% of sponsors and CROs are using or planning to use decentralised clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Source: veeva.com/resources/veeva-digital-clinical-trials-survey-report
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1711335240411537518?s=20
#blockchainforhealth #TRL
According to an industry-wide survey, 87% of sponsors and CROs are using or planning to use decentralised clinical trials (DCTs) within the next 12 months.
Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.
Source: veeva.com/resources/veeva-digital-clinical-trials-survey-report
⚡️ Trade $TRL at bit.ly/tradeTRL
🗣 Help us spread the news on Twitter:
https://x.com/triallofficial/status/1711335240411537518?s=20
#blockchainforhealth #TRL